Literature DB >> 11014347

Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients.

B R Lauwerys1, N Garot, J C Renauld, F A Houssiau.   

Abstract

OBJECTIVE: Many systemic lupus erythematosus (SLE) patients display impaired cellular immune responses against allo- or recall antigens. Given the down-regulating properties of interleukin-10 (IL-10) on antigen-presenting cell functions, this study was undertaken to investigate whether the well-known overproduction of IL-10 by SLE peripheral blood mononuclear cells (PBMC) was involved in this process.
METHODS: We measured the proliferation of SLE or control PBMC against irradiated allogeneic dendritic cells in the absence or presence of antibodies blocking IL-10 activity, or in the absence or presence of IL-12.
RESULTS: As a group, SLE PBMC proliferated against allogeneic targets less than control PBMC. However, SLE patients could be categorized as good responders or poor responders according to the amplitude of their allogeneic response. Interestingly, serum IL-10 concentrations were significantly higher in the poor responders than in the good responders or in the controls, and addition of antibodies blocking IL-10 activity significantly increased the proliferative responses of the group. We confirmed the role of IL-10 in the impaired allogeneic responses displayed by SLE PBMC by demonstrating that addition of IL-10-containing SLE PBMC supernatants inhibited a normal allogeneic response between unrelated healthy controls, and by showing that this inhibitory effect was commensurate with the concentrations of IL-10 measured in the supernatants. In this experimental setting, we also demonstrated that IL-10-containing SLE PBMC supernatants inhibited IL-12 p35 and IL-12 p40 gene expression. Consistent with the last observation, we found that addition of exogenous IL-12 restored the proliferation of poor-responder SLE patients' PBMC.
CONCLUSION: Taken together, these results indicate that dysregulation of the IL-10/IL-12 balance plays a critical role in the impaired cellular immune responses observed in SLE patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014347     DOI: 10.1002/1529-0131(200009)43:9<1976::AID-ANR8>3.0.CO;2-V

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

Review 1.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

2.  Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides.

Authors:  Petar Lenert; Adam Goeken; Barry S Handwerger; Robert F Ashman
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.317

3.  Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling.

Authors:  Christian M Hedrich; Thomas Rauen; Sokratis A Apostolidis; Alexandros P Grammatikos; Noe Rodriguez Rodriguez; Christina Ioannidis; Vasileios C Kyttaris; Jose C Crispin; George C Tsokos
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-03       Impact factor: 11.205

4.  A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis.

Authors:  Ramalingam Bethunaickan; Celine C Berthier; Meera Ramanujam; Ranjit Sahu; Weijia Zhang; Yezou Sun; Erwin P Bottinger; Lionel Ivashkiv; Matthias Kretzler; Anne Davidson
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

5.  Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon α on lupus endothelial cell progenitors.

Authors:  Alyssa M Cates; Victoria I Holden; Emily M Myers; Carolyne K Smith; Mariana J Kaplan; J Michelle Kahlenberg
Journal:  Rheumatology (Oxford)       Date:  2014-11-20       Impact factor: 7.580

Review 6.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

Review 7.  Pathogenesis of systemic lupus erythematosus.

Authors:  C C Mok; C S Lau
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

Review 8.  Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.

Authors:  Desmond Yat Hin Yap; Kar Neng Lai
Journal:  J Biomed Biotechnol       Date:  2010-05-06

Review 9.  Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus.

Authors:  Hui Peng; Wei Wang; Mo Zhou; Rui Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2013-05-25       Impact factor: 2.980

10.  Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus.

Authors:  Peter Gergely; Brian Niland; Nick Gonchoroff; Rudolf Pullmann; Paul E Phillips; Andras Perl
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.